Axsome's CEO on the launches of Auvelity and Sunosi, and the year ahead

Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV

Bausch + Lomb's Brent Saunders on the launch of two dry eye therapies and an update on BeautyHealth and Roam

Mammoth Biosciences' Trevor Martin on using ultra-compact CRISPR systems to go after extra-hepatic indications in-vivo

Recursion's Chris Gibson on the potential utility of machine learning and AI in drug development

Curevo's CEO describes P2 data released this week showing that amezosvatein may have a better profile than Shingrix

Altimmune CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon

Biotech veteran Harvey Berger on why he joined Kojin Therapeutics

A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller

Tarsus' CEO on the launch XDEMVY and additional programs that will be reading out in 2024

John Oyler shares an update on BeiGene during San Francisco Healthcare Week

Madrigal's CEO discusses the NASH field ahead of a key FDA decision date in March

Galápagos CEO Paul Stoffels on the company's $3.8B cash balance and decentralized CAR-T program

Alnylam CEO Yvonne Greenstreet previews 2024

Argenx's CEO on using FcRn to target IgG mediated autoimmune diseases

The CEO of Maze Therapeutics' shares his perspective on FTC's scuttling of his company's licensing deal with Sanofi

Daphne Zohar shares the history of the founding of Karuna and the business model of PureTech

Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more

Christophe Weber describes Takeda's global perspective on R&D and business development

Vlad Coric talks about the pipeline 'New Biohaven' has in motion after Pfizer's acquisition of its CGRPs